Morgan Stanley analyst James Quigley downgraded Bayer to Equal Weight from Overweight with a price target of EUR 62, down from EUR 80. Bayer continues to look attractive on valuation terms, but Quigley sees limited upside catalysts, thinks Crop growth will be held back by glyphosate pricing headwinds and calls 2023 an investment year in Pharma.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BAYRY: